The translational potential of PLK inhibitors in treating SCLC is supported by our demonstration that the drug sensitivity profile of the SCLC cell lines reflects what is observed clinically for metastatic SCLC tumors [16]. This evidence concerns the gene PLK1 and small cell lung carcinoma.